HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
A phase 2 trial of HS-20089 in ovarian cancer and endometrial cancer, run by Hansoh BioMedical R&D Company, now recruiting.
Overview
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer is a phase 2 interventional study registered as NCT06014190 by Hansoh BioMedical R&D Company, with 460 participants planned, started 2023-12-18 and due to reach its primary completion in 2025-12-31. Interventions recorded: HS-20089. Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialHS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Shares HS-20089, Ovarian cancer.
- PersonRobert S. Mannel
Shares Endometrial cancer, Ovarian cancer.
- PersonKaren H. Lu
Shares Endometrial cancer, Ovarian cancer.
- PersonMatthew A. Powell
Shares Endometrial cancer, Ovarian cancer.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Ovarian cancer.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Ovarian cancer.
- PersonJalid Sehouli
Shares Endometrial cancer, Ovarian cancer.
- PersonSébastien Armanet
Shares Endometrial cancer, Ovarian cancer.